Trials / Completed
CompletedNCT01521494
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 183 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 | |
| DRUG | PA21 | |
| DRUG | PA21 | |
| DRUG | PA21 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-01-11
- Primary completion
- 2012-07-03
- Completion
- 2012-07-03
- First posted
- 2012-01-30
- Last updated
- 2018-08-23
- Results posted
- 2018-08-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01521494. Inclusion in this directory is not an endorsement.